Home › Funds › Avidity Partners Management LP › DNTH

Avidity Partners Management LP position in DNTH

DIANTHUS THERAPEUTICS INC COM · Health Care

Avidity Partners Management LP reported holding 2,104,184 shares of DNTH (DIANTHUS THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$205.1M, representing 32.85% of its reported portfolio and ranking #1 among its reported holdings. Avidity Partners Management LP has disclosed DNTH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.10M sh
Reported value held$205.12M
Portfolio Weight32.85%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Avidity Partners Management LP's DNTH position evolved

Avidity Partners Management LP first disclosed a stake in DNTH in Q3 2023 at 1,217,554 shares (US$16.6M). The position peaked in Q2 2026 at 2,104,184 shares, worth US$205.1M. Across 12 filings, Avidity Partners Management LP increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 2,104,184 shares valued at US$205.1M. Notable position changes include a 123% increase in Q1 2024 (shares fell 14% over the following quarter), a 40% trim in Q1 2025 (shares rose 3% over the following quarter), a 84% increase in Q3 2025 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.22M $16.64M New
Q4 2023 1.22M $12.66M Hold
Q1 2024 2.72M $81.53M Add
Q2 2024 2.92M $75.50M Add
Q3 2024 2.92M $79.87M Hold
Q4 2024 2.87M $62.63M Reduce
Q1 2025 1.72M $31.22M Reduce
Q2 2025 1.74M $32.47M Add
Q3 2025 3.20M $126.08M Add
Q4 2025 2.10M $86.71M Reduce
Q1 2026 2.10M $176.58M Hold
Q2 2026 2.10M $205.12M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNTH and 13F data

DNTH (DIANTHUS THERAPEUTICS INC COM) is a Health Care company. 72 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Octagon Capital Advisors LP (US$179.5M), TCG Crossover Management, LLC (US$163.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNTH

All DNTH fund holders →

FAQ

How long has Avidity Partners Management LP held DNTH?

Avidity Partners Management LP has disclosed DNTH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Avidity Partners Management LP's current position in DNTH?

As of Q2 2026, Avidity Partners Management LP holds 2.10M shares of DNTH (DIANTHUS THERAPEUTICS INC COM), valued at $205.12M, representing 32.85% of its reported portfolio and ranking #1.

Has Avidity Partners Management LP been buying or selling DNTH?

In the latest 13F filing (Q2 2026), Avidity Partners Management LP held unchanged its position in DNTH. The position peaked in Q2 2026 at 2.10M shares.

Which other funds hold DNTH?

Other major institutional holders of DNTH include Fairmount Funds Management LLC, Octagon Capital Advisors LP, TCG Crossover Management, LLC, among 72 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.